Protective effect of Clostridium tyrobutyricum in acute dextran sodium sulphate-induced colitis: Differential regulation of tumour necrosis factor-α and interleukin-18 in BALB/c and severe combined immunodeficiency mice

Clinical and Experimental Immunology

Volumn 167, Issue 2, 2012, Pages 356-365

  Hudcovic, T ^a   Kolinska, J ^b   Klepetar, J ^b   Stepankova, R ^a   Rezanka, T ^a   Srutkova, D ^a   Schwarzer, M ^a   Erban, V ^c   Du, Z ^a   Wells, J M ^d   Hrncir, T ^a   Tlaskalova Hogenova, H ^a   Kozakova, H ^a  

^a INSTITUTE OF MICROBIOLOGY   (Czech Republic)

^b INSTITUTE OF PHYSIOLOGY   (Czech Republic)

^c FOOD RESEARCH INSTITUTE PRAGUE   (Czech Republic)

^d WAGENINGEN UNIVERSITY   (Netherlands)

Author keywords

Butyrate; Clostridium tyrobutyricum; Confocal fluorimetry; Dextran sodium sulphate induced colitis; SCID mice

Indexed keywords

BUTYRIC ACID; CD11B ANTIGEN; DEXTRAN SULFATE; GASTROINTESTINAL MUCOSA PROTECTIVE AGENT; INTERLEUKIN 18; MUCIN 2; PROBIOTIC AGENT; PROTEIN ZO1; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLOSTRIDIUM TYROBUTYRICUM; COLITIS; CONTROLLED STUDY; DISEASE SEVERITY; HISTOPATHOLOGY; IMMUNOREGULATION; INTESTINAL BLEEDING; LAMINA PROPRIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN EXPRESSION; RECTUM PROLAPSE;

ACUTE DISEASE; ADMINISTRATION, RECTAL; ANIMALS; ANTIGENS, CD11B; BACTERIAL TRANSLOCATION; BUTYRATES; CLOSTRIDIUM TYROBUTYRICUM; COLITIS, ULCERATIVE; COLON; DEXTRAN SULFATE; FATTY ACIDS; IMMUNOCOMPETENCE; INTERLEUKIN-18; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; MICE, SCID; MUCIN-2; MUCINS; PHOSPHOPROTEINS; PROBIOTICS; SEVERE COMBINED IMMUNODEFICIENCY; SPECIFIC PATHOGEN-FREE ORGANISMS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84855768263     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2011.04498.x     Document Type: Article

References (52)

1. Tlaskalova-Hogenova H, Tuckova L, Stepankova R etal. Involvement of innate immunity in the development of inflammatory and autoimmune diseases. Ann NY Acad Sci 2005; 1051:787-98.
2. Frolova L, Drastich P, Rossmann P, Klimesova K, Tlaskalova-Hogenova H. Expression of Toll-like receptor 2 (TLR2), TLR4, and CD14 in biopsy samples of patients with inflammatory bowel diseases: upregulated expression of TLR2 in terminal ileum of patients with ulcerative colitis. J Histochem Cytochem 2008; 56:267-74.
3. Cooper HS, Murthy SN, Shah RS, Sedergran DJ. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest 1993; 69:238-49.
4. Dieleman LA, Ridwan BU, Tennyson GS, Beagley KW, Bucy RP, Elson CO. Dextran sulfate sodium-induced colitis occurs in severe combined immunodeficient mice. Gastroenterology 1994; 107:1643-52.
5. Stepankova R, Powrie F, Kofronova O etal. Segmented filamentous bacteria in a defined bacterial cocktail induces intestinal inflammation in SCID mice reconstituted with CD45RBhigh CD4+ T cells. Inflamm Bowel Dis 2007; 13:1202-11.
6. Hudcovic T, Stepankova R, Cebra J, Tlaskalova-Hogenova H. The role of microflora in the development of intestinal inflammation: acute and chronic colitis induced by dextran sulfate in germ-free and conventionally reared immunocompetent and immunodeficient mice. Folia Microbiol 2001; 46:565-72.
7. Johansson ME, Gustafsson JK, Sjoberg KE etal. Bacteria penetrate the inner mucus layer before inflammation in the dextran sulfate colitis model. PLoS ONE 2010; 5:e12238.
8. Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y, Nakaya R. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 1990; 98:694-702.
9. Tytgat KM, Bovelander FJ, Opdam FJ, Einerhand AW, Buller HA, Dekker J. Biosynthesis of rat MUC2 in colon and its analogy with human MUC2. Biochem J 1995; 309: 221-9.
10. Renes IB, Boshuizen JA, Van Nispen DJ etal. Alterations in Muc2 biosynthesis and secretion during dextran sulfate sodium-induced colitis. Am J Physiol 2002; 282:G382-9.
11. Araki Y, Fujiyama Y, Andoh A, Koyama S, Kanauchi O, Bamba T. The dietary combination of germinated barley foodstuff plus Clostridium butyricum suppresses the dextran sulfate sodium-induced experimental colitis in rats. Scand J Gastroenterol 2000; 35:1060-7.
12. Gaudier E, Rival M, Buisine MP, Robineau I, Hoebler C. Butyrate enemas upregulate Muc genes expression but decrease adherent mucus thickness in mice colon. Physiol Res 2009; 58:111-19.
13. Venkatraman A, Ramakrishna BS, Pulimood AB, Patra S, Murthy S. Increased permeability in dextran sulphate colitis in rats: time course of development and effect of butyrate. Scand J Gastroenterol 2000; 35:1053-9.
14. Ulluwishewa D, Anderson RC, McNabb WC, Moughan PJ, Wells JM, Roy NC. Regulation of tight junction permeability by intestinal bacteria and dietary components. J Nutr 2011; 141:769-76.
15. Karczewski J, Troost FJ, Konings I etal. Regulation of human epithelial tight junction proteins by Lactobacillus plantarum in vivo and protective effects on the epithelial barrier. Am J Physiol 2010; 298:G851-9.
16. Zyrek AA, Cichon C, Helms S, Enders C, Sonnenborn U, Schmidt MA. Molecular mechanisms underlying the probiotic effects of Escherichia coli Nissle 1917 involve ZO-2 and PKCzeta redistribution resulting in tight junction and epithelial barrier repair. Cell Microbiol 2007; 9:804-16.
17. Desreumaux P, Colombel JF. Intestinal microflora and chronic inflammatory bowel diseases. Gastroenterol Clin Biol 2001; 25:C89-93.
18. Nanda Kumar NS, Balamurugan R, Jayakanthan K, Pulimood A, Pugazhendhi S, Ramakrishna BS. Probiotic administration alters the gut flora and attenuates colitis in mice administered dextran sodium sulfate. J Gastroenterol Hepatol 2008; 23:1834-9.
19. Peran L, Camuesco D, Comalada M etal. A comparative study of the preventative effects exerted by three probiotics, Bifidobacterium lactis, Lactobacillus casei and Lactobacillus acidophilus, in the TNBS model of rat colitis. J Appl Microbiol 2007; 103:836-44.
20. Hamer HM, Jonkers D, Venema K, Vanhoutvin S, Troost FJ, Brummer RJ. Review article: the role of butyrate on colonic function. Aliment Pharmacol Ther 2008; 27:104-19.
21. Okamoto T, Sasaki M, Tsujikawa T, Fujiyama Y, Bamba T, Kusunoki M. Preventive efficacy of butyrate enemas and oral administration of Clostridium butyricum M588 in dextran sodium sulfate-induced colitis in rats. J Gastroenterol 2000; 35:341-6.
22. Schallehn G, Wolff MH. Morphological changes in human embryonic lung fibroblasts caused by cytotoxins of various Clostridium species. Zentralbl Bakteriol Mikrobiol Hyg 1988; 267:367-78.
23. Khoruts A, Sadowsky MJ. Therapeutic transplantation of the distal gut microbiota. Mucosal Immunol 2011; 4:4-7.
24. Topping DL, Clifton PM. Short-chain fatty acids and human colonic function: roles of resistant starch and nonstarch polysaccharides. Physiol Rev 2001; 81:1031-64.
25. Melgar S, Karlsson A, Michaelsson E. Acute colitis induced by dextran sulfate sodium progresses to chronicity in C57BL/6 but not in BALB/c mice: correlation between symptoms and inflammation. Am J Physiol 2005; 288:G1328-38.
26. Bauer C, Loher F, Dauer M etal. The ICE inhibitor pralnacasan prevents DSS-induced colitis in C57BL/6 mice and suppresses IP-10 mRNA but not TNF-alpha mRNA expression. Dig Dis Sci 2007; 52:1642-52.
27. Elinav E, Strowig T, Kau AL etal. NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis. Cell 2011; 145:745-57.
28. Jacobs LR, Huber PW. Regional distribution and alterations of lectin binding to colorectal mucin in mucosal biopsies from controls and subjects with inflammatory bowel diseases. J Clin Invest 1985; 75:112-18.
29. Van der Sluis M, De Koning BA, De Bruijn AC etal. Muc2-deficient mice spontaneously develop colitis, indicating that MUC2 is critical for colonic protection. Gastroenterology 2006; 131:117-29.
30. Amit-Romach E, Reifen R, Uni Z. Mucosal function in rat jejunum and ileum is altered by induction of colitis. Int J Molecular Med 2006; 18:721-7.
31. Einerhand AW, Renes IB, Makkink MK, van der Sluis M, Buller HA, Dekker J. Role of mucins in inflammatory bowel disease: important lessons from experimental models. Eur J Gastroenterol Hepatol 2002; 14:757-65.
32. Poritz LS, Garver KI, Green C, Fitzpatrick L, Ruggiero F, Koltun WA. Loss of the tight junction protein ZO-1 in dextran sulfate sodium induced colitis. J Surg Res 2007; 140:12-19.
33. Shintani N, Nakajima T, Okamoto T, Kondo T, Nakamura N, Mayumi T. Involvement of CD4+ T cells in the development of dextran sulfate sodium-induced experimental colitis and suppressive effect of IgG on their action. Gen Pharmacol 1998; 31:477-81.
34. Friswell M, Campbell B, Rhodes J. The role of bacteria in the pathogenesis of inflammatory bowel disease. Gut Liver 2010; 4:295-306.
35. Siegmund B, Fantuzzi G, Rieder F etal. Neutralization of interleukin-18 reduces severity in murine colitis and intestinal IFN-gamma and TNF-alpha production. Am J Physiol Regul Integr Comp Physiol 2001; 281:R1264-73.
36. Kolinska J, Lisa V, Clark JA etal. Constitutive expression of IL-18 and IL-18R in differentiated IEC-6 cells: effect of TNF-alpha and IFN-gamma treatment. J Interferon Cytokine Res 2008; 28:287-96.
37. Bauer C, Duewell P, Mayer C etal. Colitis induced in mice with dextran sulfate sodium (DSS) is mediated by the NLRP3 inflammasome. Gut 2010; 59:1192-9.
38. Siegmund B. Interleukin-18 in intestinal inflammation: friend and foe? Immunity 2010; 32:300-2.
39. Zaki MH, Boyd KL, Vogel P, Kastan MB, Lamkanfi M, Kanneganti TD. The NLRP3 inflammasome protects against loss of epithelial integrity and mortality during experimental colitis. Immunity 2010; 32:379-91.
40. Dupaul-Chicoine J, Yeretssian G, Doiron K etal. Control of intestinal homeostasis, colitis, and colitis-associated colorectal cancer by the inflammatory caspases. Immunity 2010; 32:367-78.
41. Mahida YR. The key role of macrophages in the immunopathogenesis of inflammatory bowel disease. Inflamm Bowel Dis 2000; 6:21-33.
42. Reinecker HC, Steffen M, Witthoeft T etal. Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol 1993; 94:174-81.
43. Thibault R, Blachier F, Darcy-Vrillon B, de Coppet P, Bourreille A, Segain JP. Butyrate utilization by the colonic mucosa in inflammatory bowel diseases: a transport deficiency. Inflam Bowel Dis 2010; 16:684-95.
44. Noor SO, Ridgway K, Scovell L etal. Ulcerative colitis and irritable bowel patients exhibit distinct abnormalities of the gut microbiota. BMC Gastroenterol 2010; 10:134.
45. Willing BP, Finlay BB. Gut microbiology: fitting into the intestinal neighbourhood. Curr Biol 2009; 19:R457-9.
46. Wachtershauser A, Stein J. Rationale for the luminal provision of butyrate in intestinal diseases. Eur J Nutr 2000; 39:164-71.
47. Hamer HM, Jonkers DM, Vanhoutvin SA etal. Effect of butyrate enemas on inflammation and antioxidant status in the colonic mucosa of patients with ulcerative colitis in remission. Clin Nutr 2010; 29:738-44.
48. Cario E, Gerken G, Podolsky DK. Toll-like receptor 2 enhances ZO-1-associated intestinal epithelial barrier integrity via protein kinase C. Gastroenterology 2004; 127:224-38.
49. Nafday SM, Chen W, Peng L, Babyatsky MW, Holzman IR, Lin J. Short-chain fatty acids induce colonic mucosal injury in rats with various postnatal ages. Pediatr Res 2005; 57:201-4.
50. Nancey S, Moussata D, Graber I, Claudel S, Saurin JC, Flourie B. Tumor necrosis factor alpha reduces butyrate oxidation in vitro in human colonic mucosa: a link from inflammatory process to mucosal damage? Inflam Bowel Dis 2005; 11:559-66.
51. Kalina U, Koyama N, Hosoda T etal. Enhanced production of IL-18 in butyrate-treated intestinal epithelium by stimulation of the proximal promoter region. Eur J Immunol 2002; 32:2635-43.
52. Kolinska J, Zakostelecka M, Schwarzer M, Stepankova R, Hudcovic T, Kozakova H. Effect of nonpathogenic Escherichia coli monoassociation on small intestinal brush-border glycoconjugate moieties and cytokine production after colonization in ex-germ-free rats and piglets. Int J Interferon Cytokine Mediat Res 2010; 2:73-84.